High-frequency-grade adverse events after receiving triple therapy and dual therapy were elevated aspartate aminotransferase (314/388, 81.0%), elevated alanine aminotransferase (285/388, 73.5%), and hypertension (238/388, 61.3%). This evidence concerns the gene GPT and hypertensive disorder.